Maike de Wit - Concepedia

Author

Maike de Wit

Also Known As

Eric Terrebonne, Jozefina Casuscelli, Kyran Dowling, M de Wit, M. De Wit, M. de Wit, MAIKE DE WIT, Maike De Wit, Maike Wit, Maike de Wit

207

Publications

16.3K

Citations

H-Index

Concepts

All Affiliations

Vivantes Klinikum Universität Hamburg University Medical Center Hamburg-Eppendorf Charité - Universitätsmedizin Berlin Heidelberg University

About

Maike de Wit is an author at Vivantes Klinikum specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	26	3.2K
2	Health Sciences	12	12	1.1K
3	Applied Physiology	2	2	253
4	Anesthesia	1	1	11
5	Biomedical Engineering	1	1	11

Maike de Wit

Publications

13.7K

Citations

H-Index

Page 1

	Year	Citations
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer Scott Antonia, Augusto Villegas, Davey B. Daniel, New England Journal of Medicine	2017	4.4K
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC Scott Antonia, Augusto Villegas, Davey B. Daniel, New England Journal of Medicine	2018	2.7K
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky, The Lancet NanomedicineOncologyPancreatic CancerMedicineFolinic Acid	2015	1.2K
Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group Andreas Engert, Petra Schiller, Andreas Josting, Journal of Clinical Oncology	2003	456
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial Corinne Faivre‐Finn, David Vicente, Takayasu Kurata, Journal of Thoracic Oncology	2021	455
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer J. Beyer, Peter Albers, Renske Altena, Annals of Oncology	2012	320
Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial Andreas Engert, Jeremy Franklin, Hans Theodor Eich, Journal of Clinical Oncology	2007	260
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II S. Krege, J. Beyer, Rainer Souchon, European Urology Germ Cell CancerGenitourinary CancerMedicineCancer ManagementEuropean Consensus Conference	2008	252
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV Susanne Saußele, Marie-Paloma Krauß, Rüdiger Hehlmann, Blood	2015	197
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study Rina Hui, Mustafa Özgüroğlu, Augusto Villegas, The Lancet Oncology	2019	185

Page 1